TrialsgrambetaRCTs are beautiful

SOLO-1

2018

Maintenance Olaparib in Newly Diagnosed BRCA-Mutated Advanced Ovarian Cancer

In 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.

Result

Efficacy: Progression-free survivalHR 0.3

Below 1 favours olaparib for two years, above 1 favours placebo.

Also reported: 7-yr OS HR 0.55; 7-yr OS 67.0% vs 46.5%.

Original publication
Subtopic
BRCA-mutated ovarian
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Moore K, et al. N Engl J Med. 2018;379(26):2495-2505.doi 10.1056/NEJMoa1810858

Discussion & critique

Defined PARP-inhibitor maintenance as first-line standard in BRCA-mutated advanced ovarian cancer. PAOLA-1 extended this to the HRD-positive population on olaparib + bevacizumab.